Mechanisms of resistance to vascular endothelial growth factor blockade

Cancer

Volumn 118, Issue 14, 2012, Pages 3455-3467

  Abdullah, Shaad E ^a   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

cancer; resistance; signaling; vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN 1; AXITINIB; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; COLONY STIMULATING FACTOR; EPHRIN; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; LINIFANIB; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER RESISTANCE; CELL HETEROGENEITY; CELL HYPOXIA; CELL MIGRATION; CELL TYPE; COLORECTAL CANCER; DRUG TARGETING; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE MUTATION; GLIOBLASTOMA; GYNECOLOGIC CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; OVARY CANCER; PANCREAS CANCER; PANCREAS TUMOR; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; THYROID CANCER; TREATMENT DURATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863305116     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26540     Document Type: Review

References (107)

1. Crivellato E, Ribatti D,. Aristotle: the first student of angiogenesis. Leukemia. 2006; 20: 1209-1210. (Pubitemid 43905822)
2. Risau W, Flamme I,. Vasculogenesis. Annu Rev Cell Dev Biol. 1995; 11: 73-91. (Pubitemid 26019602)
3. Risau W,. Mechanisms of angiogenesis. Nature. 1997; 386: 671-674. (Pubitemid 27193480)
4. Burri PH, Djonov V,. Intussusceptive angiogenesis-the alternative to capillary sprouting. Mol Aspects Med. 2002; 23: S1-S27. (Pubitemid 36092148)
5. Carmeliet P,. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000; 6: 389-395. (Pubitemid 30208155)
6. Daly ME, Makris A, Reed M, Lewis CE,. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst. 2003; 95: 1660-1673. (Pubitemid 37509075)
7. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002; 160: 1405-1423. (Pubitemid 34411644)
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-1487. (Pubitemid 24356306)
9. Bergers G, Benjamin LE,. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-410. (Pubitemid 37328844)
10. Crivellato E, Nico B, Vacca A, Ribatti D,. B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. Haematologica. 2003; 88: 671-678. (Pubitemid 36781594)
11. Ferrara N, Alitalo K,. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5: 1359-1364.
12. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
13. O'Reilly MS,. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs. 1997; 15: 5-13. (Pubitemid 27217747)
14. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A. 1999; 96: 14888-14893. (Pubitemid 30019735)
15. Folkman J,. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175: 409-416.
16. Folkman J, Klagsbrun M,. Angiogenic factors. Science. 1987; 235: 442-447. (Pubitemid 17009577)
17. Folkman J,. Fighting cancer by attacking its blood supply. Sci Am. 1996; 275: 150-154.
18. Hanahan D, Folkman J,. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86: 353-364. (Pubitemid 26272076)
19. Genentech, Inc. AVASTIN (bevacizumab) solution for intravenous infusion [package insert]. South San Francisco, CA: Genentech, Inc.; 2010.
20. Pfizer Inc. SUTENT (sunitinib malate) capsules, oral [package insert]. New York: Pfizer Inc.; 2011.
21. Bayer Healthcare Pharmaceuticals Inc. NEXAVAR (sorafenib) tablets, oral [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; 2010.
22. GlaxoSmithKline. Votrient (pazopanib) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
23. Prior BM, Yang HT, Terjung RL,. What makes vessels grow with exercise training? J Appl Physiol. 2004; 97: 1119-1128. (Pubitemid 39121441)
24. Murdoch C, Muthana M, Coffelt SB, Lewis CE,. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8: 618-631.
25. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF,. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 983-985.
26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N,. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246: 1306-1309. (Pubitemid 20066716)
27. Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol. 1994; 266: H1588-H1595. (Pubitemid 24150792)
28. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003; 9: 604-613. (Pubitemid 36597108)
29. Abdel-Malak NA, Srikant CB, Kristof AS, Magder SA, Di Battista JA, Hussain SN,. Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. Blood. 2008; 111: 4145-4154.
30. Lopez-Lopez C, LeRoith D, Torres-Aleman I,. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A. 2004; 101: 9833-9838. (Pubitemid 38869322)
31. Pugh CW, Ratcliffe PJ,. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9: 677-684. (Pubitemid 36749216)
32. Carey DJ,. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997; 327 (pt 1): 1-16. (Pubitemid 27455453)
33. Avraamides CJ, Garmy-Susini B, Varner JA,. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008; 8: 604-617.
34. Folkman J,. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007; 6: 273-286. (Pubitemid 46505878)
35. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027. (Pubitemid 46202320)
36. Yamazaki Y, Matsunaga Y, Tokunaga Y, Obayashi S, Saito M, Morita T,. Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J Biol Chem. 2009; 284: 9885-9891.
37. Takahashi H, Shibuya M,. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (London). 2005; 109: 227-241. (Pubitemid 41337127)
38. Lohela M, Bry M, Tammela T, Alitalo K,. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009; 21: 154-165.
39. Aase K, Lymboussaki A, Kaipainen A, Olofsson B, Alitalo K, Eriksson U,. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev Dyn. 1999; 215: 12-25. (Pubitemid 29215700)
40. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004; 64: 7822-7835. (Pubitemid 39446915)
41. Schneider BP, Radovich M, Miller KD,. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res. 2009; 15: 5297-5302.
42. Veikkola T, Alitalo K,. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999; 9: 211-220. (Pubitemid 29273837)
43. Neufeld G, Kessler O,. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer. 2008; 8: 632-645.
44. Menakuru SR, Brown NJ, Staton CA, Reed MW,. Angiogenesis in pre-malignant conditions. Br J Cancer. 2008; 99: 1961-1966.
45. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
46. Kerbel RS,. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006; 312: 1171-1175. (Pubitemid 43801134)
47. Blagosklonny MV,. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther. 2005; 4: 1307-1310. (Pubitemid 43131171)
48. Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2008; 68: 183-196.
49. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005; 65: 4389-4400. (Pubitemid 40775678)
50. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68: 4774-4782.
51. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res. 2008; 14: 6146-6153.
52. Fujisaka Y, Yamada Y, Yamamoto N, et al. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010; 66: 935-943.
53. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006; 66: 8715-8721. (Pubitemid 44449188)
54. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006; 5: 995-1006. (Pubitemid 43724600)
55. Shankar DB, Li J, Tapang P, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 2007; 109: 3400-3408. (Pubitemid 46572529)
56. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005; 23: 5474-5483.
57. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008; 14: 7272-7283.
58. Kerbel R, Folkman J,. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2: 727-739. (Pubitemid 37328908)
59. Wu E, Palmer N, Tian Z, et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells [serial online]. PLoS One. 2008; 3: e3794.
60. Abramsson A, Lindblom P, Betsholtz C,. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003; 112: 1142-1151. (Pubitemid 38056291)
61. Rusnati M, Presta M,. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007; 13: 2025-2044. (Pubitemid 47040487)
62. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M,. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 159-178. (Pubitemid 40616114)
63. Casanovas O, Hicklin DJ, Bergers G, Hanahan D,. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8: 299-309. (Pubitemid 41443415)
64. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8: 592-603.
65. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004; 18: 338-340.
66. Kano MR, Morishita Y, Iwata C, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005; 118: 3759-3768. (Pubitemid 41309422)
67. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007; 117: 2766-2777. (Pubitemid 47529608)
68. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
69. Rini BI,. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 2009; 115: 2306-2312.
70. Eikesdal HP, Kalluri R,. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol. 2009; 19: 310-317.
71. Grépin R, Pagès G,. Molecular mechanisms of resistance to tumour anti-angiogenic strategies [serial online]. J Oncol 2010: 835680, 2010.
72. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11: 83-95. (Pubitemid 46075199)
73. Alitalo K, Tammela T, Petrova TV,. Lymphangiogenesis in development and human disease. Nature. 2005; 438: 946-953. (Pubitemid 43093960)
74. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009; 15: 21-34.
75. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-231.
76. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS,. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15: 232-239.
77. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS,. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295: 1526-1528. (Pubitemid 34174008)
78. Ferrara N,. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol. 2010; 17: 219-224.
79. Xouri G, Christian S,. Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol. 2010; 21: 40-46.
80. Raza A, Franklin MJ, Dudek AZ,. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010; 85: 593-598.
81. Shaked Y, Tang T, Woloszynek J, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 2009; 69: 7524-7528.
82. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS,. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104: 17069-17074. (Pubitemid 350210993)
83. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010; 28: 453-459.
84. Kim E, Moore J, Huang J, et al. All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg. 2001; 36: 287-290. (Pubitemid 32112542)
85. Yang JC,. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004; 10: 6367S-6370S. (Pubitemid 39287493)
86. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111. (Pubitemid 350296300)
87. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-434. (Pubitemid 36910021)
88. Folkman J, Kalluri R,. Cancer without disease. Nature. 2004; 427: 787. (Pubitemid 38297724)
89. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004; 351: 250-259. (Pubitemid 38916042)
90. Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004; 64: 8249-8255. (Pubitemid 39491762)
91. Hida K, Klagsbrun M,. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005; 65: 2507-2510. (Pubitemid 40490041)
92. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med. 2010; 207: 491-503.
93. Huang J, Soffer SZ, Kim ES, et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res. 2004; 2: 36-42. (Pubitemid 38167106)
94. Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ,. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Update. 2004; 7: 289-300. (Pubitemid 39469101)
95. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004; 165: 35-52. (Pubitemid 38821812)
96. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284: 1994-1998. (Pubitemid 29309448)
97. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J,. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer. 2001; 91: 1500-1509. (Pubitemid 32319261)
98. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000; 2: 306-314.
99. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001; 61: 6624-6628. (Pubitemid 32896475)
100. Hillen F, Griffioen AW,. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007; 26: 489-502. (Pubitemid 350115123)
101. Rapisarda A, Shoemaker RH, Melillo G,. Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle. 2009; 8: 4040-4043.
102. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007; 131: 463-475. (Pubitemid 350007692)
103. Hersey P, Sosman J, O'Day S, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or-dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010; 116: 1526-1534.
104. Saidi A, Hagedorn M, Allain N, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer. 2009; 125: 1054-1064.
105. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009; 106: 6742-6747.
106. Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010; 115: 1461-1471.
107. Yan M, Plowman GD,. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 2007; 13: 7243-7246.